How to develop better HPLC drug impurity analysis methods

Significance of the topic

Accurate impurity profiling by HPLC and UHPLC is critical to ensuring drug safety, regulatory compliance, and consistent product quality for small molecules and biologics. Low-level impurities and degradation products can affect efficacy, patient safety, and lead to product recalls. Optimized impurity methods reduce false positives/negatives, increase laboratory throughput, and ensure reliable method transfer between sites.

Objectives and study overview

This guidance condenses best practices for developing robust impurity analysis methods using HPLC/UHPLC. Key aims are to maximize selectivity and sensitivity, minimize method variability, and provide strategies for quantitation when certified standards are unavailable. Practical recommendations address column selection, detection choices, sample handling, forced-degradation studies, and techniques for resolving coelution and matrix effects.

Methodology and instrumentation

Core methodological elements emphasized for impurity workflows:

• Define regulatory thresholds early: follow ICH reporting thresholds (0.05% for maximum daily dose ≤2 g/day; 0.03% for >2 g/day) to set limits of quantitation and method sensitivity.
• Map impurity sources: include degradation-related and process-related impurities to design targeted separations and stability studies.
• Column selection: choose stationary phase selectivity and particle morphology to optimize resolution, robustness, and throughput; right particle design lowers solvent consumption and run time.
• Match injection solvent to initial mobile phase strength to avoid distortion of early-eluting low-level impurities.
• Use forced-degradation (stress) studies under heat, light, oxidative and hydrolytic conditions to reveal degradation pathways and guide method specificity.
• Assess sample stability (benchtop and autosampler) to detect handling- or storage-induced impurity changes.
• Implement system wash and equilibration cycles to mitigate ghost peaks from carryover and contamination.
• Evaluate matrix effects and apply sample cleanup (filtration, SPE, diversion to waste) where needed to reduce interferences.
• Plan for method robustness and transferability by testing small variations in pH, temperature and flow; simplify manual steps where possible to reduce transfer risk.

Used Instrumentation

Instrumentation considerations highlighted in the guidance:

• Detectors: combine complementary detectors (UV-Vis, charged aerosol detector (CAD), mass spectrometry) to expand measurable compound classes—UV for chromophores, CAD for non-chromophores and semi-volatiles, MS for identity confirmation.
• Detector performance: ensure sufficient dynamic range (typically ≥4 orders of magnitude) and low-nanogram LOQs so APIs and trace impurities can be quantified in a single run.
• Charged aerosol detection specifics: CAD provides near-universal response useful when individual standards are unavailable; however, CAD sensitivity can be influenced by analyte volatility, mobile-phase organic content, and evaporation/temperature control.
• Mitigation strategies for nebulizer-based detectors: use inverse gradient compensation to maintain response uniformity during gradient elution and control evaporation temperature for semi-volatiles.
• Multidimensional separations: use 2D-LC (e.g., multi-heart-cutting) to resolve hidden coeluting impurities that single-dimension LC cannot separate.

Main results and discussion

The consolidated recommendations provide several practical outcomes for impurity method development:

• Pairing the correct stationary phase with attention to particle morphology measurably improves resolution, reduces run time, and increases robustness.
• Using both internal and external standards yields more reliable quantitation: internal standards monitor recovery during sample preparation; external standards create calibration curves for accurate response-to-concentration relationships.
• When certified standards are not available, near-universal detectors such as CAD enable semi-quantitative estimates using a single calibrant, though physicochemical influences on response must be controlled.
• 2D-LC and complementary detection significantly reduce risk of undetected impurities caused by coelution and limited detector selectivity.
• System cleanliness (regular washes) and high-quality consumables (gold-grade vials) reduce data variance and ghost peaks, improving repeatability for trace-level impurities.

Benefits and practical applications

Practical benefits of following these guidelines include:

• Improved analytical accuracy and confidence in impurity profiling for regulatory submissions and QC release.
• Higher method robustness and easier cross-lab transferability by minimizing sensitivity to modest method parameter changes.
• Expanded capability to quantify compounds lacking chromophores or ionization efficiency via CAD and multimodal detection strategies.
• Reduced risk of QC failures and recalls through better detection of degradation and process-related impurities.

Future trends and potential applications

Emerging and expanding areas relevant to impurity analysis:

• Wider adoption of 2D-LC workflows for routine impurity profiling to uncover coeluting degradation products and complex impurity profiles.
• Further integration of CAD with temperature and evaporation control to improve quantification of semi-volatile species and broaden linear response range.
• Increased use of multimodal detector arrays (UV/CAD/MS) and advanced data libraries to enable high-confidence identification and quantification in a single run.
• Continuous improvement of method transfer tools (standardized protocols, automation) to reduce inter-laboratory variability.

Conclusion

Robust HPLC/UHPLC impurity methods require a holistic approach: start by defining regulatory limits, map impurity sources, choose the appropriate stationary phase and detection scheme, and validate method robustness and sample stability. Complementary detectors, forced-degradation studies, 2D separations, and good laboratory practices (system cleaning, high-quality vials) all contribute to reliable impurity detection and quantitation. Where standards are lacking, near-universal detectors such as CAD provide practical fallback options but require careful control of detector-influencing parameters.

References

Listed technical and literature resources cited in the original guidance (titles as provided):

• Quantifying more with less: Implementing charged aerosol detection to improve drug safety
• A reliable UHPLC/UV/CAD/MS multidetector method for routine quantification and library matching of extractables and leachables in pharmaceutical-grade plastics
• Characterization of polysorbate 80 in (bio)pharmaceuticals using HPLC-CAD
• Impurity profiling of PEGylated myristoyl diglyceride, DMG-PEG 2000, a functional excipient used in mRNA lipid nanoparticle formulations
• Characterization of four saturated fatty acids using gradient HPLC-CAD highlighting optimized evaporation temperature control features
• Applications of Hydrophilic Interaction Chromatography in Pharmaceutical Impurity Profiling: A Comprehensive Review of Two Decades
• Evaluation of custom injection programs and larger internal diameter capillary for strong solvent sample effects mitigation in liquid chromatography
• A Look at the Past & Future Impacts of HPLC-CAD Technology
• HPLC-CAD Learning Center
• Analysis of pharmaceutical impurities using multiheartcutting 2D LC coupled with UV-charged aerosol MS detection
• High-Performance Liquid Chromatography Methods for Determining the Purity of Drugs with Weak UV Chromophores – A Review
• Matrix effects demystified: Strategies for resolving challenges in analytical separations of complex samples